WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
SHANGHAI, May 27, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Drug Product Facility 15 (DP15), located at the company's Fengxian site in Shanghai, achieved GMP release in April. The facil...
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included i...
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the structural completion and key equipment arrival at its microbial commercial manufacturing site in Chengdu, marking a...
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
* Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clients * Zero non-conformities demonstrates company's robust quality management system SHANGHAI, April 14, 2026 /PRNewswire/ -- WuXi Biologics...
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record growth and a transformative leap in operational sophistication. Th...
WuXi Biologics Reports Record 2025 Annual Results
* Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY * IFRS gross profit margin expanded to 46.0% (+500 bps YoY); adjusted gross profit margin increased to 48.8% (+340bps) * EBITDA rose 38.1% YoY and IFRS net profit increased 45.3% YoY; ...
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation
SINGAPORE, March 12, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma Excelle...
WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline
SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and auto...
JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
* Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects * 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients * Complex modalities are WuXi Biologics' core growth engi...
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have r...
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have r...
WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland
DUNDALK, Ireland, Nov. 23, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development, and manufacturing, announced that its subsidiary WuXi Vaccines, engaged in ...
WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing
WUXI, China, June 21, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it planned to expand the new state-of-the-art ...
WuXi Biologics Commenced Construction of a 48,000 L Integrated Manufacturing Center for Innovative Biologics in Chengdu
CHENGDU, China, May 16, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that the construction of a new 1.3 million sq. ft....
